Abbott

U.S. court grants Abbott's request for preliminary injunction against Biaxin XL genericsSHORT

Published in Health Insurance Law Weekly, December 25th, 2005

The U.S. District Court in Chicago, Ilinois, has granted Abbott Laboratories' request for a preliminary injunction that will prevent unauthorized generic copies of Abbott's Biaxin XL (clarithromycin) from Ranbaxy and Andrx.

It is expected that a full patent infringement trial will take place in 2006, although no date has been set. Biaxin XL is indicated for respiratory tract infections.

Abbott is a broad-based healthcare company discovering, developing, manufacturing and marketing pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

The company employs more than 60,000 people and markets its...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly

Source: Health Insurance Law Weekly (2005-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry